The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Barclays Upgrades Sartorius AG and Subsidiary on Post-COVID Recovery Potential
Barclays has upgraded Sartorius AG and its subsidiary Sartorius Stedim Biotech to Overweight, citing a post-COVID recovery in the bioprocessing industry. The firm notes both stocks are undervalued compared to peers, with SRT expected to see 12% order growth in FY25 and a significant increase in free cash flow. Price targets have been raised for both companies, reflecting anticipated positive earnings momentum as customer demand returns.
sartorius stedim biotech shares rise on barclays upgrade and positive outlook
Sartorius Stedim Biotech's share price surged over 2.5% following an upgrade by Barclays, which raised its recommendation from 'in-line weighted' to 'overweight' and increased the price target from €200 to €250. Analysts noted the pharmaceutical sector is nearing a return to pre-Covid levels, yet both Sartorius companies remain undervalued compared to peers.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.